...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus
【24h】

Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus

机译:铌取代的杂多钨酸盐对乙型肝炎病毒的合成,表征和生物学活性

获取原文
获取原文并翻译 | 示例

摘要

To synthesise and characterize the polyoxometalate Cs 2K 4Na[SiW 9Nb 3O 40] H 2O 1 for its anti-hepatitis B virus (HBV) properties by using the HepG2.2.15 cell. The methylthiazol tetrazolium assay was used to evaluate the growth inhibitory effect of Compound 1 on HepG2.2.15 cell. By using ELISA and real-time PCR, respectively, the presence of extracellular hepatitis B surface antigen (HBsAg), e antigen (HBeAg), and HBV DNA were measured. The levels of intracellular HBV DNA and mRNA were determined by using Southern blot or reverse-transcription- PCR, respectively. Intracellular distribution of antigen were measured by Western blot. A 1995 lmol/L concentration of the commercially-available hepatitis B drug, adefovir dipivoxil (ADV), was required to achieve 50% cytotoxicity against cultured cells (CC50) by day nine; in contrast, only 1747 lmol/L of Compound 1 was required for the same result. Treatment of HepG2.2.15 cells with Compound 1 effectively suppress the secretion of HBV antigens and HBV DNA in a dose-dependent and time-dependent manner. IC50 values were determined to be 80 lmol/L for HBsAg, 75 lmol/L for HBeAg and 3.72 lmol/L for supernatant HBV DNA at day nine post-exposure, as opposed to 266, 296, 30.09 lmol/L, respectively, for ADV. Intracellular HBV DNA, mRNA and antigen were also found to be decreased by Compound 1. The same dose of ADV yielded a significantly less robust inhibitory effect. Compound 1 can clear HBV from hepatic cells and may represent a therapeutic agent to treat HBV infection.
机译:为了合成和表征多金属氧酸盐Cs 2K 4Na [SiW 9Nb 3O 40] H 2O 1的抗乙型肝炎病毒(HBV)特性,使用HepG2.2.15细胞。甲基噻唑四唑鎓测定用于评估化合物1对HepG2.2.15细胞的生长抑制作用。通过分别使用ELISA和实时PCR,测量了细胞外乙型肝炎表面抗原(HBsAg),e抗原(HBeAg)和HBV DNA的存在。分别通过Southern印迹或逆转录-PCR确定细胞内HBV DNA和mRNA的水平。通过Western印迹测量抗原的细胞内分布。为了在第九天之前达到对培养细胞的50%细胞毒性(CC50),需要1995 lmol / L浓度的市售乙型肝炎药物阿德福韦酯(ADV)。相反,只需1747 lmol / L的化合物1即可获得相同的结果。用化合物1处理HepG2.2.15细胞以剂量依赖性和时间依赖性方式有效抑制HBV抗原和HBV DNA的分泌。暴露后第9天,HBsAg的IC50值为80 lmol / L,HBeAg的IC50值为75 lmol / L,HBV DNA上清液的IC50值为3.72 lmol / L,而HBsAg的IC50值分别为266、296、30.09 lmol / L。 ADV。还发现化合物1降低了细胞内HBV DNA,mRNA和抗原。相同剂量的ADV产生的抑制作用明显较弱。化合物1可以从肝细胞清除HBV,并且可以代表治疗HBV感染的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号